Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study)-Reference-Cited by-同舟云学术

Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study)

Published:2020-10-15 Issue:12 Volume:11 Page:2959-2977
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Ishii Hitoshi^ORCID,Nakajima Hiroki,Kamei Nozomu,Niiya Tetsuji,Hiyoshi Toru,Hiramori Yuko,Ohtsu Shigeyuki,Noto Takashi,Shimono Dai

Funder

AstraZeneca K.K.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13300-020-00941-8.pdf

Reference41 articles.

1. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care. 2018;41:2669–701.

2. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetes Care. 2020;43:487–93.

3. Haneda M, Noda M, Origasa H, et al. Japanese clinical practice guideline for diabetes 2016. Diabetol Int. 2018;9:1–45.

4. The Japan Diabetes Society (2020) Japanese Clinical Practice Guideline for Diabetes 2020–2021. Bunkodo.

5. Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf. 2014;5:138–46.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health state utility values of type 2 diabetes mellitus and related complications: a systematic review and meta-regression;Health and Quality of Life Outcomes;2024-09-07

2. The impact of dipeptidyl peptidase 4 inhibitors on health-related quality of life in patients with type 2 diabetes mellitus: a systematic review and meta-analysis;Quality of Life Research;2024-08-03

3. Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus;European Journal of Medicinal Chemistry Reports;2024-08

4. Protective effects and mechanisms of dapagliflozin on renal ischemia/reperfusion injury;Transplant Immunology;2024-06

5. Effects of Metabolic Medicine and Metabolic Surgery on Patient-Reported Outcomes Among Patients with Type 2 Diabetes;Metabolic Syndrome and Related Disorders;2022-11-01